Skip to main content
Premium Trial:

Request an Annual Quote

NCI Renews Cancer Biomarker Research Support Program

NEW YORK (GenomeWeb News) – The National Cancer Institute is continuing its support for a program under which cancer researchers can receive assistance in conducting validations of biomarker programs.
 
The NCI said yesterday that the goal of the Program for Rapid, Independent Diagnostic Evaluation, or PRIDE, is to help researchers advance biomarkers from the lab to clinically viable tests through cross-laboratory validation. The PRIDE program’s efforts include the development, refinement, and use of assays, reagents, methods, and tests.
 
The PRIDE program is part of the NCI’s Early Detection Research Network. The EDRN began in 2000 to help investigators with rapid evaluation of the reproducibility, portability, and precision of their technologies and biomarker assays. It will be supported by NCI for another year, according to Donald Johnsey of the NCI’s Division of Cancer Prevention.
 
More information about the PRIDE program can be found here.
 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.